Lecanemab-irmb · Regulatory label update

FDA supplemental approval: Lecanemab Autoinjector (Efficacy)

U.S. Food and Drug Administration · July 13, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a regulatory approval action by the FDA for a supplemental indication of lecanemab in autoinjector form (LEQEMBI IQLIK), approved 13 July 2026. The record documents the regulatory decision only and does not contain clinical trial results, efficacy outcomes, or safety data.

What was studied

Regulatory label update. Intervention: Lecanemab autoinjector (LEQEMBI IQLIK), 360 mg/1.8 mL subcutaneous injection.

Key findings

FDA approved supplemental application BLA761375 for lecanemab autoinjector formulation (LEQEMBI IQLIK) on 2026-07-13 Product formulation: 360 mg/1.8 mL (200 mg/mL) injectable, subcutaneous

Safety

This regulatory record does not contain clinical trial results, efficacy data, or safety outcomes

Who this may help

This approval expands the lecanemab delivery format to an autoinjector, which may improve convenience and patient adherence compared to infusion or manual injection; however, this regulatory record does not report efficacy, safety, or comparative clinical outcomes. Clinicians should consult the approved product labeling and underlying clinical trial data for efficacy and safety information.

Plain-language summary

FDA supplemental approval of lecanemab autoinjector formulation; regulatory action record that does not contain clinical trial efficacy or safety data.

Study design

As stated by the source record.

InterventionLecanemab autoinjector (LEQEMBI IQLIK), 360 mg/1.8 mL subcutaneous injection

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-13

Product strength360 mg/1.8 mL (200 mg/mL)

Clinical bottom line

Caveats

This regulatory record does not contain clinical trial results, efficacy data, or safety outcomes
No sample size, population characteristics, or comparative trial data provided
Approval is of the autoinjector formulation only; efficacy basis is not described in this record
Actual clinical outcomes and comparative benefit must be obtained from full product labeling and underlying studies

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory approval record; no clinical study design reported

Directness

insufficient

Record documents approval action only; no efficacy or clinical outcome data

Consistency

insufficient

No comparative data or replication study results provided

Risk of bias

insufficient

Regulatory record; trial methodology and bias assessment not reported

Sample adequacy

insufficient

No sample size, population, or trial enrollment data reported

Source abstract

Drugs@FDA record for application BLA761375. This is a regulatory action record, not a clinical study. Brand name: LECANEMAB AUTOINJECTOR. Active ingredient: LECANEMAB-IRMB. Sponsor: EISAI INC. Submission type: SUPPL (supplement). Submission class: Efficacy. Approval status date: 2026-07-13. Products: LEQEMBI IQLIK, INJECTABLE, SUBCUTANEOUS, LECANEMAB-IRMB 360MG/1.8ML(200MG/ML).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

EisaiLecanemab-irmb